BioMedNewsBreaks

TuesdayDec 22, 2020 1:21 pm

BioMedNewsBreaks – TPT Global Tech Inc. (TPTW) Announces Launch of ‘QuikLAB’ and ‘QuikPASS’ Apps

TPT Global Tech (OTC: TPTW), a provider of telecommunications, medical technology, media content for domestic and international syndication as well as technology solutions, today announced the release of two new products and services for use at its TPT Med Tech division. These include its "QuikLAB" App, designed for use in monitoring patient testing and vaccination history, and its "QuikPASS" Mobile App. QuikPASS is designed to allow entrance to any facility or country based on patient test and vaccination results on a real-time basis worldwide. The QuikPASS App will be offered free of charge to U.S. and international consumer markets. TPT…

Continue Reading

TuesdayDec 22, 2020 12:28 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Reaches Another Significant Milestone with Scaled-up Production of Clinical-Grade REQORSA(TM)

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced its completion of the manufacturing scale-up of REQORSA(TM) immunogene therapy. Subject to satisfactory completion of final testing currently underway, the clinical-grade production is intended to supply Genprex’s upcoming Acclaim-1 and Acclaim-2 clinical trials for the treatment of non-small cell lung cancer. The company recently announced the successful manufacturing technology transfer to commercial contract development and manufacturing organizations (“CDMOs”) as well as the successful engineering run of REQORSA, which passed all testing specifications. “The scaled-up production of clinical-grade REQORSA is yet another significant manufacturing milestone…

Continue Reading

TuesdayDec 22, 2020 11:13 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) CEO Talks Benefits of Disposable Brain Diagnostic Tools

Brain Scientific (OTCQB: BRSF) co-founder and CEO Boris Goldstein penned a recent article for “Healthcare” magazine. Titled “Brain Scientific: Neurology’s need for disposable solutions,” the article provides an overview of the need for new devices in the neurology market and the advantages of disposable brain diagnostic tools. Goldstein noted that his interest in brain diagnostic tools began when he was studying at college, where he used clustering analysis for Rorschach testing. As the founder of BrainRX, he was involved in pre-Alzheimer diagnostic and software development, and he was always searching for places to obtain data for artificial analysis or data correlation.…

Continue Reading

TuesdayDec 22, 2020 10:30 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Finalizes Agreement to Provide RPM Solution to Presbyterian Medical Services

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has inked an agreement with one of the largest integrated healthcare systems in the state of New Mexico to provide remote patient monitoring (“RPM”). The partnership with Presbyterian Medical Services begins Jan. 1, 2021. The agreement, which followed a rigorous request for proposal (“RFP”) process, reflects DRIO’s shift in focus to B2B2C and outlines the company’s commitment to provide access to Dario's next-generation, AI-powered digital therapeutics tools and quality care to patients living with chronic conditions, such as diabetes and hypertension. "We are very pleased to partner with Presbyterian Medical Services in…

Continue Reading

FridayDec 18, 2020 2:24 pm

BioMedNewsBreaks – Why Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Is ‘One to Watch’

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company that is focused on establishing a new standard of care in visualizing cancer. The company’s initial focus is on bladder cancer and its first product is the i/Blue Imaging(TM) System. Based on advanced optics, light sensors and employing patented ultrasensitive imaging technology, Imagin believes its system can significantly improve surgeons’ ability to visualize and remove cancer cells. A recent article discussing the company reads, “Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with…

Continue Reading

FridayDec 18, 2020 1:33 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Marks Significant Milestone with Commencement of CSE Trading

Tryp Therapeutics (CSE: TRYP) today announced that its common shares have commenced trading on the Canadian Securities Exchange ("CSE") under the symbol "TRYP" effective Dec. 18, 2020. "Trading on the CSE is a significant milestone in Tryp's mission to transform the treatment of neuropsychiatric diseases with safe and effective psychedelic medicines," said Tryp CEO James Kuo, MD. "All of the drugs within our portfolio have well characterized safety profiles including our drug candidate for soft tissue sarcoma, which has been in multiple phase 2 clinical trials. We are looking forward to utilizing the experience and dedication of our management team…

Continue Reading

FridayDec 18, 2020 1:11 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Shines Spotlight on Innovative Media in Exclusive Interview

Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery, was recently featured in an exclusive audio interview with NetworkNewsWire. During the interview, POAI CEO Carl Schwartz noted recent milestones, outlined strategic goals and provided key updates on the company’s four impressive subsidiaries: Skyline Medical, TumorGenesis, Soluble Biotech and Helomics. Schwartz indicated that the original purpose of TumorGenesis was to develop a lab media to replace rats and mice in scientific industries as well as the testing of tumors. Predictive Oncology has succeeded in developing the first…

Continue Reading

FridayDec 18, 2020 9:45 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Commencement, Pricing of Underwritten Public Offering

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, has announced the commencement and pricing of an underwritten public offering. The offering consists of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the “Common Stock”), and 2,000,000 shares of its Series D convertible preferred stock (“Series D Preferred Stock”) at a public offering price of $21.16 per share. VistaGen expects $100 million in gross proceeds from the offering, before underwriting discounts, commissions and estimated offering expenses. Subject to…

Continue Reading

FridayDec 18, 2020 8:30 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Hosts Conference Call to Discuss IND Approval, Phase 2 Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, on Thursday announced that it will be holding a conference call to discuss its recently approved Investigational New Drug (“IND”) application involving its lead product candidate Berubicin for the treatment of Glioblastoma Multiforme (“GBM”). The company also intends to discuss its planned Phase 2 Berubicin clinical trial on the call slated for Friday, December 18, 2020 at 8:30 AM ET. Interested parties may access the call by dialing (800) 226-2188 (domestic) or (602) 563-8462 (international)…

Continue Reading

ThursdayDec 17, 2020 12:17 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Announces NeuroCap for Children, Enters Pediatric Market

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has launched its next-generation, disposable EEG cap, NeuroCap(TM) in a children’s size, making the innovative product available for use in the U.S. pediatric market. The smaller NeuroCap headset is designed to overcome common challenges that arise when conducting an electroencephalogram (“EEG”), such as measuring and marking the patient’s head, and following sanitation protocols. The pediatric NeuroCap also addresses the need for comfort, speed and reliability within the pediatric population. BRSF’s disposable, pre-gelled NeuroCap features 19 active EEG channels and 22 electrodes and can be quickly, easily and accurately applied by any…

Continue Reading